IPRs and Access to Medicines: New Evidence

Michelle Wein January 7, 2015
January 7, 2015

Those in the global health community often allege that prices of new innovative drugs under patent make them unaffordable to most people in developing countries because of the absence of generic competition. A new report, however, finds good news about the relationship between IPRs and access to innovative medicines.